Examining HPV Vaccination Practices and Differences Among Providers in Virginia.
Adolescent
Adult
Child
Cross-Sectional Studies
Female
Health Knowledge, Attitudes, Practice
Health Personnel
/ psychology
Humans
Male
Middle Aged
Papillomaviridae
/ isolation & purification
Papillomavirus Infections
/ epidemiology
Papillomavirus Vaccines
/ administration & dosage
Practice Patterns, Physicians'
/ statistics & numerical data
Surveys and Questionnaires
Vaccination
/ methods
Virginia
/ epidemiology
Young Adult
Cancer
Cervical cancer
HPV vaccine
Health care providers
Journal
Journal of cancer education : the official journal of the American Association for Cancer Education
ISSN: 1543-0154
Titre abrégé: J Cancer Educ
Pays: England
ID NLM: 8610343
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
7
12
2018
medline:
15
12
2020
entrez:
7
12
2018
Statut:
ppublish
Résumé
Virginia has some of the lowest HPV vaccination rates, despite being one of the few states in the USA requiring adolescent girls receive the vaccine. Provider characteristics may be an important factor in HPV vaccination. Thus, the present study assessed provider vaccination, practices, knowledge about the vaccine, and confidence in performing behaviors related to the vaccine. We conducted a cross-sectional electronic survey in a large health care system in Northern Virginia. A total of 53 responses were received. Only respondents who reported seeing adolescent patients were included in analyses (N = 42). Differences in responses were examined by provider age, gender, and type. Respondents reported recommending the vaccine a high percent of the time to eligible patients and had overall high levels of knowledge and confidence. Male providers recommended the vaccine to boys ages 11-12, less frequently than female providers. Providers age 50 and over recommended the vaccine to boys ages 11-12 less frequently than younger providers. This study shows that there are some gaps in HPV vaccine recommendation practices among providers. These gaps may be one reason for the low uptake of the HPV vaccine among adolescents. Thus, educational and training interventions of providers could be considered.
Identifiants
pubmed: 30520008
doi: 10.1007/s13187-018-1455-0
pii: 10.1007/s13187-018-1455-0
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-164Références
Vaccine. 2016 Feb 3;34(6):762-8
pubmed: 26752063
Vaccine. 2012 Jun 22;30(30):4511-6
pubmed: 22561142
EBioMedicine. 2015 Jun 23;2(8):891-7
pubmed: 26425696
J Adolesc Health. 2017 Aug;61(2):252-258
pubmed: 28462786
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1673-9
pubmed: 26494764
J Pediatr Adolesc Gynecol. 2005 Dec;18(6):391-8
pubmed: 16338604
Vaccine. 2012 Feb 8;30(7):1269-75
pubmed: 22230593
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8
pubmed: 27561081
J Infect Dis. 2013 Aug 1;208(3):385-93
pubmed: 23785124
Expert Rev Vaccines. 2014 Nov;13(11):1279-90
pubmed: 25256262
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2354-61
pubmed: 21949110
EBioMedicine. 2015 Jul 02;2(8):792-3
pubmed: 26425679
Hum Vaccin Immunother. 2015;11(6):1331-6
pubmed: 25945895
BMC Med Res Methodol. 2015 Apr 09;15:32
pubmed: 25888346